At a glance
ClinicalIndex Comparison RecordN/ACompleted· 551 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open, Non-interventional, Retrospective, Comparative, Multicenter Follow-up Study in Patients Included in the Previously Completed Clinical Study PCB305/04, to Assess Longer-term Recurrence Rates in Patients After Hexvix® (Cysview®)Fluorescence Cystoscopy/Transurethral Resection of the Bladder (TURB) or White Light Cystoscopy/TURB
In Brief
An observational study for Bladder Cancer. Completed, enrolled 551 participants across 24 sites in 5 countries.
Detailed Summary
The study is intended to investigate whether the improved initial detection and resection of bladder cancer lesions in patients with non-muscle invasive bladder cancer with Hexvix (Cysview) fluorescence cystoscopy/TURB will lead to a longer-term reduction in recurrences compared to standard white light cystoscopy/TURB.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBladder Cancer
CountriesAustria, Canada, Germany, Netherlands, United States
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2010
First PostedJul 2010
Primary CompletionDec 2010
TodayJul 2026
First PostedJul 20, 2010
Enrollment StartJun 1, 2010
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 16.0 years ago